Table 2.
Univariate and Multivariate Liner Regression Associating Baseline Factors With ATLCs.
| Characteristic | Regression coefficient | 95% CI | P |
|---|---|---|---|
| Univariate analysis | |||
| Age (years) | 1.414 | −6.470 to 9.299 | .723 |
| Sex (male vs female) | −103.327 | −274.322 to 67.669 | .234 |
| ECOG (0-1 vs 2) | 8.393 | −171.665 to 188.451 | .927 |
| Smoker (No vs others) | −44.374 | −209.880 to 121.133 | .596 |
| Underlying respiratory system disease (No vs others) | −57.295 | −223.423 to 108.832 | .496 |
| Tumor diameter (1 mm) | −9.045 | −16.423 to −1.668 | .017 |
| Tumor location (Peripheral vs central) | −199.446 | −378.800 to −20.092 | .030 |
| Pre-SBRT TLCs (1 cells/µL) | −0.484 | −0.593 to −0.376 | <.001 |
| GTV (1 cm3) | −3.904 | −7.001 to 0.807 | .014 |
| PTV (1 cm3) | −3.164 | −5.264 to −1.063 | .003 |
| Lung V5 (1%) | −17.154 | −25.873 to −8.435 | <.001 |
| Heart V15 (1%) | −9.389 | −17.657 to −1.120 | .026 |
| Fractionation (50 Gy/5 fractions vs 60 Gy/10 fractions) | −292.823 | −460.300 to −125.345 | .001 |
| Radiation time (seconds) | −0.067 | −0.109 to −0.025 | .002 |
| Multivariate analysis | |||
| Pre-SBRT TLCs (cells/µL) | −0.494 | −0.598 to −0.389 | <.001 |
| Fractionation (50 Gy/5 fractions vs 60 Gy/10 fractions) | −240.561 | −377.892 to −103.230 | .001 |
| PTV (1 cm3) | −8.404 | −14.712 to −2.096 | .010 |
Abbreviations: ATLC, alteration of total lymphocyte count; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; SBRT, stereotactic body radiation therapy; GTV, gross tumor volume; PTV, planning target volume; Lung V5, the percentage of total lung volume receiving at least 5 Gy; Heart V15, the percentage of total heart volume receiving at least 15 Gy.